Society Letters

Endocrine Society Comments on FDA Global Rare Disease Network

July 28, 2020

To: Lowell Schiller, Principal Associate Commissioner for Policy, U.S. Food and Drug Administration

"Several endocrine conditions, including acromegaly, adrenocortical carcinoma, growth hormone deficiency, Cushing’s syndrome, and familial chylomicronemia syndrome (FCS), qualify as rare diseases, and patients still lack effective treatments for many of these and other conditions. We enthusiastically support the Rare Diseases Cures Accelerator and welcome the opportunity to participate in a global clinical trial network for rare diseases. Our comments are aimed at ensuring the immediate and long-term success of such an initiative."

arrowRead the Full Summary

Last Updated:
Take Action

Make Your Voice Heard

Take Action
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!